Dr. Santiago Garcia, MD
Claim this profileThe Christ Hospital
Affiliated Hospitals
The Christ Hospital
Abbott Northwestern Hospital
Clinical Trials Santiago Garcia, MD is currently running
Proteomics Analysis
for Heart Valve Disease
The purpose of the HALT Biomarkers study are to identify a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT) and can be used to supplement the diagnosis of HALT; to characterize changes in circulating proteins after treatment of HALT with systemic anticoagulation; and to identify circulating proteins that predict the occurrence of HALT. The study population will be adult patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) or bioprosthetic valve degeneration. Enrollment will continue until 30 patients with HALT are identified for completion of phase 1. Based on a HALT incidence rate of 10%, we anticipate enrolling 300 patients. Patients are enrolled prior to undergoing transfemoral TAVR. Blood samples, clinical data and echocardiograms will be collected at the following timepoints: baseline (pre-TAVR, T0), post-TAVR (pre-discharge, T1), 30-day follow-up (window 3-9 weeks, T2), and 6-month follow-up (T3). Cardiac 4D CT will be performed at the 30-day follow-up visit to screen for the occurrence of HALT. Patients with HALT will be treated with systemic anticoagulation for 5-6 months, at which point a follow-up CT scan and blood sample will be obtained. Control subjects will also undergo a 6-month study visit with blood sample collection. The study will be conducted within two phases. Phase 1 will serve as a derivation / discovery study in which candidate protein biomarkers of HALT will be identified. Once this is successfully completed, a second cohort will be enrolled within phase 2. Phase 2 will be performed under the auspices a future contract or amendment and will seek to cross-validate the initial study findings.
Recruiting
1 award
Phase 1
3 criteria
J-Valve Transfemoral System
for Aortic Regurgitation
The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR). A Cardiac Magnetic Resonance (CMR) sub-study will examine if intervention for AR translates to improved ventricular remodeling, the impact of LV remodeling on clinical outcomes and quality of life, as well as volumetric and myocardial differences between genders.
Recruiting
1 award
N/A
2 criteria
More about Santiago Garcia, MD
Clinical Trial Related
8 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Santiago Garcia, MD has experience with
- Edwards PASCAL System
- ACURATE Neo2™ Transfemoral TAVR System
- Medtronic CoreValve TAVR System
- Edwards SAPIEN 3 TAVR System
- ACURATE Prime™ Transfemoral TAVR System XL
- Sentinel® Cerebral Protection System
Breakdown of trials Santiago Garcia, MD has run
Von Willebrand Disease
Aortic Valve Disease
Aortic Valve Stenosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Santiago Garcia, MD specialize in?
Santiago Garcia, MD focuses on Von Willebrand Disease and Aortic Valve Disease. In particular, much of their work with Von Willebrand Disease has involved treating patients, or patients who are undergoing treatment.
Is Santiago Garcia, MD currently recruiting for clinical trials?
Yes, Santiago Garcia, MD is currently recruiting for 4 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Santiago Garcia, MD has studied deeply?
Yes, Santiago Garcia, MD has studied treatments such as Edwards PASCAL System, ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System.
What is the best way to schedule an appointment with Santiago Garcia, MD?
Apply for one of the trials that Santiago Garcia, MD is conducting.
What is the office address of Santiago Garcia, MD?
The office of Santiago Garcia, MD is located at: The Christ Hospital, Cincinnati, Ohio 45219 United States. This is the address for their practice at the The Christ Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.